Newer therapeutic agents for asthma

Disease-a-Month

Volumn 45, Issue 4, 1999, Pages 117-

  Deykin, Aaron ^a   Israel, Elliot ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CYCLOSPORIN; DRUG DERIVATIVE; FLUTICASONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIDOCAINE; METHOTREXATE; SALBUTAMOL; SALMETEROL; TOLUENESULFONIC ACID DERIVATIVE; ZAFIRLUKAST;

ASTHMA; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HUMAN; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CYCLOSPORINE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LEUKOTRIENE ANTAGONISTS; LIDOCAINE; METHOTREXATE; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 85045781575     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(99)90007-X     Document Type: Review

References (98)

1. Anonymous. Asthma: United States, 1982-1992. MMWR Morb Mortal Wkly Rep 1995;43:952-5.
2. Anonymous. Asthma mortality and hospitalization among children and young adults: United States, 1980-1993. MMWR Morb Mortal Wkly Rep 1996;45:350-3.
3. Smith DM, Malone DC, Lawson KA, et al. A national estimate of the economic cost of asthma. Am J Respir Crit Care Med 1997;156:787-93.
4. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6.
5. Anonymous. International consensus report on diagnosis and treatment of asthma. Clin Exp Allergy 1992;22 (Suppl 1):1-72.
6. Anonymous. Guidelines on the management of asthma. Statement by the British Thoracic Society, the Brit. Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the Brit. Assoc. of Accident and Emergency Medicine, and the Brit. Paediatric Respiratory Group. Thorax 1993;48:S1-24.
7. Anonymous. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report 2. NIH Publication 97-4051. 1997.
8. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med 1995;333:499-506.
9. Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci 1993;52:2131-43.
10. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
11. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. Ann Pharmacother 1993;27:1478-87.
12. Taylor IK, O'Shaughnessy KM, Choudry NB, et al. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J Allergy Clin Immunol 1992;89:575-83.
13. Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
14. Anderson SD, Rodwell LT, Du Toit J, et al. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 1991;100:1254-60.
15. Twentyman OP, Finnerty JP, Harris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990;336:1338-42.
16. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
17. Lotvall J, Lunde H, Ullman A, et al. Twelve months, treatment with inhaled salmeterol in asthmatic patients: effects on beta 2-receptor function and inflammatory cells. Allergy 1992;47:477-83.
18. Faurschou P. Chronic dose-ranging studies with salmeterol. Eur Respir Rev 1991;1:282-7.
19. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison of salmeterol with salbutamol in asthmatic patients: European Study Group. Eur Respir J 1992;5:1062-7.
20. D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994;271:1412-6.
21. Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am J Respir Crit Care Med 1996;154:324-8.
22. Boulet LP, Laviolette M, Boucher S, et al. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild- to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immunol 1997;99:13-21.
23. Selby C, Engleman HM, Fitzpatrick MF, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma? Am J Respir Crit Care Med 1997;155:104-8.
24. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
25. Simmons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
26. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid: Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
27. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
28. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
29. Wilding P, Clark M, Coon JT, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997;314:1441-6.
30. Crompton GK. Bronchodilator treatment in asthma: regular treatment with beta agonists remains unevaluated. BMJ 1993;306:1610.
31. Sears MR, Taylor DR. Bronchodilator treatment in asthma: increase in deaths during salmeterol treatment unexplained. BMJ 1993;306:1610-1.
32. Mann RD. Results of prescription event monitoring study of salmeterol. BMJ 1994;309:1018.
33. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990;141:859-69.
34. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32-42.
35. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
36. Evans PM, O'Connor BJ, Fuller RW, et al. Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 1993;91:643-50.
37. Boschetto P, Rogers DF, Fabbri LM, et al. Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 1991;143:605-9.
38. Mapp C, Boschetto P, dal Vecchio L, et al. Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects. Am Rev Respir Dis 1987;136:1403-7.
39. Dahl R, Johansson SA. Effect on lung function of budesonide by inhalation, terbutaline s.c. and placebo given simultaneously or as single treatments. Eur J Respir Dis Suppl 1982;122:132-7.
40. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990;141:S70-6.
41. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92.
42. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
43. Wempe JB, Tammeling EP, Postma DS, et al. Effects of budesonide and bambuterol on circadian variation of airway responsiveness and nocturnal symptoms of asthma. J Allergy Clin Immunol 1992;90:349-57.
44. Dompeling E, van Schayck CP, Molema J, et al. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992;5:945-52.
45. Salmeron S, Guerin JC, Godard P, et al. High doses of inhaled corticosteroids in unstable chronic asthma: a multicenter, double-blind, placebo-controlled study. Am Rev Respir Dis 1989;140:167-71.
46. Lacronique J, Renon D, Georges D, et al. High-dose beclomethasone: oral steroid-sparing effect in severe asthmatic patients. Eur Respir J 1991;4:807-12.
47. Toogood JH, Lefcoe NM, Haines DS, et al. Minimum dose requirements of steroid-dependent asthmatic patients for aerosol beclomethasone and oral prednisone. J Allergy Clin Immunol 1978;61:355-64.
48. English AF, Neate MS, Quint DJ, et al. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149:212A.
49. Fuller R, Johnson M, Bye A. Fluticasone propionate: An update on preclinical and clinical experience. Respir Med 1995;89 (Suppl A):3-18.
50. Anonymous. Fluticasone propionate for chronic asthma. Med Lett Drugs Ther 1996;38:83-4.
51. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.
52. Leblanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy 1994;49:380-5.
53. Sheffer AL, LaForce C, Chervinsky P, et al. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma: Fluticasone Propionate Asthma Study Group. J Fam Pract 1996;42:369-75.
54. Barnes NC, Marone G, Di Maria GU, et al. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma: International Study Group. Eur Respir J 1993;6:877-85.
55. Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma: International Study Group. Eur Respir J 1995;8:579-86.
56. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995;152:1467-73.
57. Okamoto LJ, Noonan M, DeBoisblanc BP, et al. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. Ann Allergy Asthma Immunol 1996;76:455-61.
58. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 1996;51:941-3.
59. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-6.
60. Bootsma GP, Dekhuijzen PN, Festen J, et al. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996;153:924-30.
61. Henderson WR Jr. Role of leukotrienes in asthma. Ann Allergy 1994;72:272-8.
62. Drazen J. Effects of leukotrienes on airway function. In: West JB, Crystal RG, editors. The lung: scientific foundations. Philadelphia: Lippincott-Raven; 1997. p. 1287-96.
63. Koh YY, Dupuis R, Pollice M, et al. Neutrophils recruited to the lungs of humans by segmental antigen challenge display a reduced chemotactic response to leukotriene B4. Am J Respir Cell Mol Biol 1993;8:493-9.
64. Smith LJ, Geller S, Ebright L, et al. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990;141:988-92.
65. Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
66. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
67. Dahlen B, Margolskee DJ, Zetterstrom O, et al. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-10.
68. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
69. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
70. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma: ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
71. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: the Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997;155:1235-40.
72. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in eight patients receiving zafirlukast. JAMA. In press.
73. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
74. Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931-5.
75. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
76. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
77. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
78. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial: Zileuton Study Group. J Allergy Clin Immunol 1996;98:859-71.
79. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial: Zileuton Clinical Trial Group. JAMA 1996;275:931-6.
80. Calderon E, Coffey RG, Lockey RF. Methotrexate in bronchial asthma. J Allergy Clin Immunol 1991;88:274-6.
81. Segal R, Mozes E, Yaron M, et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989;32:370-7.
82. Mullarkey MF, Webb DR, Pardee NE. Methotrexate in the treatment of steroid-dependent asthma. Ann Allergy 1986;56:347-50.
83. Mullarkey MF, Blumenstein BA, Andrade WP, et al. Methotrexate in the treatment of corticosteroid-dependent asthma: a double-blind crossover study. N Engl J Med 1988;318:603-7.
84. Shiner RJ, Nunn AJ, Chung KF, et al. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990;336:137-40.
85. Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma: a double-blind, placebo-controlled study. Ann Intern Med 1991;114:353-60.
86. Coffey MJ, Sanders G, Eschenbacher WL, et al. The role of methotrexate in the management of steroid-dependent asthma. Chest 1994;105:117-21.
87. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985;12:35-9.
88. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
89. Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144:3891-7.
90. Lagente V, Carre C, Kyriacopoulos F, et al. Inhibitory effect of cyclosporin A on eosinophil infiltration in the guinea-pig lung induced by antigen, platelet-activating factor and leukotriene B4. Eur Respir J 1994;7:921-6.
91. Szczeklik A, Nizankowska E, Dworski R, et al. Cyclosporin for steroid-dependent asthma. Allergy 1991;46:312-5.
92. Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995;8:1091-9.
93. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
94. Ohnishi T, Kita H, Mayeno AN, et al. Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin Exp Immunol 1996;104:325-31.
95. Hunt LW, Swedlund HA, Gleich GJ. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc 1996;71:361-8.
96. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991;87:976-83.
97. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
98. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993;148:1S-26S.